exenatide + Placebo

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Obesity

Conditions

Obesity, Impaired Glucose Tolerance

Trial Timeline

Apr 1, 2007 → Sep 1, 2010

NCT ID

NCT00456885

About exenatide + Placebo

exenatide + Placebo is a approved stage product being developed by Eli Lilly for Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT00456885. Target conditions include Obesity, Impaired Glucose Tolerance.

What happened to similar drugs?

20 of 20 similar drugs in Obesity were approved

Approved (20) Terminated (5) Active (0)

✅TirzepatideEli LillyApproved

✅Micafungin + MicafunginAstellas PharmaApproved

✅MicafunginAstellas PharmaApproved

✅Zonegran + PlaceboEisaiApproved

✅lorcaserin hydrochloride XR + PlaceboEisaiApproved

✅Placebo + TirzepatideEli LillyApproved

✅Tirzepatide + PlaceboEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01140893	Phase 2/3	UNKNOWN	Nov 1, 2010	—	Type 2 Diabetes
NCT01364584	Pre-clinical	Completed	Oct 1, 2010	Dec 1, 2014	Type 2 Diabetes
NCT00845507	Approved	Completed	Dec 1, 2008	Jul 1, 2015	Weight Gain
NCT00603239	Phase 3	Completed	Jan 1, 2008	Jul 1, 2009	Type 2 Diabetes Mellitus
NCT00516074	Phase 3	Completed	Sep 1, 2007	Apr 1, 2008	Type 2 Diabetes Mellitus
NCT00500370	Phase 2	Completed	Jun 1, 2007	Feb 1, 2008	Obesity
NCT00456885	Approved	Completed	Apr 1, 2007	Sep 1, 2010	Obesity
NCT00667732	Approved	Completed	Mar 1, 2007	Apr 1, 2010	Type 2 Diabetes
NCT00375492	Phase 3	Completed	Sep 1, 2006	Feb 1, 2008	Type 2 Diabetes Mellitus
NCT00324363	Phase 3	Completed	Jan 1, 2006	Apr 1, 2007	Type 2 Diabetes Mellitus
NCT00241423	Phase 2	Completed	Oct 1, 2005	Jun 1, 2007	Type 2 Diabetes Mellitus
NCT00099320	Phase 3	Completed	May 1, 2004	Aug 1, 2005	Type 2 Diabetes Mellitus

Competing Products

20 competing products in Obesity

See all competitors

Product	Company	Stage	Hype Score
MK0493	Merck	Phase 2	35
MK0557	Merck	Phase 3	40
AMG 786	Amgen	Phase 1	29
Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide Placebo	Eli Lilly	Phase 2	39
Tirzepatide	Eli Lilly	Phase 2	42
Brenipatide	Eli Lilly	Phase 1	36
Orforglipron + Placebo	Eli Lilly	Phase 3	47
TERN-601	Terns Pharmaceuticals	Phase 2	32
MBX 4291 + Placebo	MBX Biosciences	Phase 1	30
PG-102	Rani Therapeutics	Phase 1	26
Orforglipron + Placebo	Eli Lilly	Phase 1	29
Tirzepatide + Placebo	Eli Lilly	Phase 3	40
Eloralintide + Placebo	Eli Lilly	Phase 1	29
Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo	Eli Lilly	Phase 2	27
LY3437943 + Midazolam + Warfarin + Caffeine	Eli Lilly	Phase 1	29
Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection	Skye Bioscience	Phase 2	29
Tirzepatide	Eli Lilly	Approved	50
Adenosine + Regadenoson	Astellas Pharma	Pre-clinical	26
Micafungin + Micafungin	Astellas Pharma	Approved	43
Micafungin	Astellas Pharma	Approved	43